This population was less likely to be retained in care than cisgender women and cisgender men with HIV, but once engaged had similar rates of viral suppression.
The estimated prevalence of HIV in transgender women in the U.S. is about 20%, making engagement in care by this community a high priority in the fight to end the HIV epidemic.
To address knowledge gaps regarding the HIV care continuum in this population, investigators compared data on linkage to care, retention in services, and HIV suppression among 396 transgender women, 14,094 cisgender women, and 101,667 cisgender men with HIV in NA-ACCORD, a large prospective cohort of people with HIV in North America, between 2001 and 2015. The transgender women in the cohort were younger than cisgender women and cisgender men (median age, 36 vs. 40 and 44 years, respectively), more likely to be black than cisgender men (40% vs. 36%), and more likely t…
Reviewing Authors
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
Robert H. Goldstein, MD, PhD
Robert H. Goldstein, MD, PhD